familial hypercholesterolemia articles & resources on Made-in-China.com

The European Committee for Medicinal Products for Human Use Has Adopted Positive Opinion

May 31, 2013

The European Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinion for Aegerion Pharmaceuticals' marketing authorization for Lojuxta (lomitapide) hard capsules. If approved, Lojuxta will be indicated for adult ...

Tags: Marketing Authorization, Medicine

FDA Approval of Kynamro Injection Indicated for Homozygous Familial HoFH

Jan 31, 2013

Genzyme and Isis have announced the FDA approval of Kynamro (mipomersen sodium) injection indicated for homozygous familial hypercholesterolemia (HoFH). The regulatory agency approved Kynamro 200mg subcutaneous injection per week as an ...

Tags: FDA, drug, familial hypercholesterolemia therapy

Aegerion Has Received US FDA Approval to Be Used as an Adjunct to a Low-Fat Diet

Dec 28, 2012

Aegerion Pharmaceuticals' Juxtapid (lomitapide) capsules has received US FDA approval to be used as an adjunct to a low-fat diet and other lipid-lowering treatments. Juxtapid, which is a supplement to fat reduction treatments also ...

Tags: Juxtapid, US, FDA, capsules, treatments

Genzyme Submitted a New Drug Application to The FDA Seeking Approval for KYNAMRO

Dec 5, 2012

Genzyme, a Sanofi company, has submitted a new drug application to the FDA seeking approval for KYNAMRO for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). The submission is based on trial in which ...

Tags: KYNAMRO, homozygous familial hypercholesterolemia, HoFH

REGENX Biosciences Has Received FDA Orphan Drug Designation

Apr 11, 2012

REGENX BioSciences has received FDA orphan drug designation for treatment of familial hypercholesterolemia (HoFH) using NAV rAAV8 vectors. The REGENX program consists of a NAV rAAV8 vector expressing a normal copy of the human ...

Tags: orphan drug designation, familial hypercholesterolemia, clinical study

familial hypercholesterolemia

The European Committee for Medicinal Products for Human Use Has Adopted Positive Opinion

FDA Approval of Kynamro Injection Indicated for Homozygous Familial HoFH

Aegerion Has Received US FDA Approval to Be Used as an Adjunct to a Low-Fat Diet

Genzyme Submitted a New Drug Application to The FDA Seeking Approval for KYNAMRO

REGENX Biosciences Has Received FDA Orphan Drug Designation

Related Products